These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21856022)

  • 1. Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study.
    Doehner W; Todorovic J; Kennecke C; Rauchhaus M; Sandek A; Lainscak M; van Linthout S; Tschöpe C; von Haehling S; Anker SD
    Int J Cardiol; 2012 Nov; 161(3):137-42. PubMed ID: 21856022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does improved insulin sensitivity by irbesartan at the highest tolerated dose provide a benefit in non-diabetic patients with systolic heart failure already receiving standardized treatment?
    Yang D; Liu Z
    Int J Cardiol; 2013 Sep; 168(2):1572-3. PubMed ID: 23434005
    [No Abstract]   [Full Text] [Related]  

  • 3. Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study).
    Peters CD; Kjaergaard KD; Jensen JD; Christensen KL; Strandhave C; Tietze IN; Novosel MK; Bibby BM; Jespersen B
    PLoS One; 2015; 10(6):e0126882. PubMed ID: 26030651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
    Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
    Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism.
    Schäfer A; Fraccarollo D; Tas P; Schmidt I; Ertl G; Bauersachs J
    Eur J Heart Fail; 2004 Mar; 6(2):151-9. PubMed ID: 14984722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group.
    Tonkon M; Awan N; Niazi I; Hanley P; Baruch L; Wolf RA; Block AJ
    Int J Clin Pract; 2000; 54(1):11-4, 16-8. PubMed ID: 10750252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND).
    Parhofer KG; Birkeland KI; DeFronzo R; Del Prato S; Bhaumik A; Ptaszynska A
    Int J Clin Pract; 2010 Jan; 64(2):160-8. PubMed ID: 19929980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial.
    Kjaergaard KD; Peters CD; Jespersen B; Tietze IN; Madsen JK; Pedersen BB; Novosel MK; Laursen KS; Bibby BM; Strandhave C; Jensen JD
    Am J Kidney Dis; 2014 Dec; 64(6):892-901. PubMed ID: 25011693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure.
    Blanchet M; Sheppard R; Racine N; Ducharme A; Curnier D; Tardif JC; Sirois P; Lamoureux MC; De Champlain J; White M
    Am Heart J; 2005 May; 149(5):938.e1-7. PubMed ID: 15894946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.
    McMullan CJ; Lambers Heerspink HJ; Parving HH; Dwyer JP; Forman JP; de Zeeuw D
    Am J Kidney Dis; 2014 Nov; 64(5):714-22. PubMed ID: 25064674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
    Beer C; Blacker D; Bynevelt M; Hankey GJ; Puddey IB
    Int J Stroke; 2012 Feb; 7(2):104-11. PubMed ID: 22044557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction.
    Yip GW; Wang M; Wang T; Chan S; Fung JW; Yeung L; Yip T; Lau ST; Lau CP; Tang MO; Yu CM; Sanderson JE
    Heart; 2008 May; 94(5):573-80. PubMed ID: 18208835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
    Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
    Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial.
    Salcedo-Alejos M; Banda-Espinoza F; Rodríguez-Morán M; Guerrero-Romero F
    Nephrol Dial Transplant; 2005 Oct; 20(10):2120-5. PubMed ID: 16091379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.